首页> 外文OA文献 >Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle
【2h】

Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle

机译:多基源混合饲料牛的天然牛呼吸道患者肺上皮衬液中肺上皮衬液中的药代动力学和药效学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objectives of this study were to determine (i) whether an association exists between individual pharmacokinetic parameters and treatment outcome when feeder cattle were diagnosed with bovine respiratory disease (BRD) and treated with gamithromycin (Zactran)at the label dose and (ii) whether there was a stronger association between treatment outcome and gamithromycin concentration in plasma or in the pulmonary epithelial lining fluid (PELF) effect compartment. The study design was a prospective, blinded, randomized clinical trial utilizing three groups of 60 (362–592 lb) steers/bulls randomly allocated within origin to sham injection or gamithromycin mass medication. Cattle were evaluated daily for signs of BRD by a veterinarian blinded to treatment. Animals meeting the BRD case definition were enrolled and allocated to a sample collection scheme consisting of samples for bacterial isolation (bronchoalveolar lavage fluid and nasopharyngeal swabs) and gamithromycin concentration determination (PELF and plasma). Gamithromycin susceptibility of M. haemolytica (n = 287) and P. multocida (n = 257) were determined using broth microdilution with frozen panels containing gamithromycin at concentrations from 0.03 to 16 ug/mL. A two-compartment plasma pharmacokinetic model with an additional compartment for gamithromycin in PELF was developed using rich data sets from published and unpublished studies. The sparse data from our study were then fit to this model using nonlinear mixed effects modeling to estimate individual parameter values. The resulting parameter estimates were used to simulate full time–concentration profiles for each animal in this study. These profiles were analyzed using noncompartmental methods so that PK/PD indices (AUC24/MIC, AUC∞/MIC, CMAX/MIC) could be calculated for plasma and PELF (also Tu3eMIC) for each individual. The calculated PK/PD indices were indicative that for both M. haemolytica and P. multocida a higher drug exposure in terms of concentration, and duration of exposure relative to the MIC of the target pathogen, was favorable to a successful case outcome. A significant association was found between treatment success and PELF AUC0–24/MIC for P. multocida. The calves in this study demonstrated an increased clearance and volume of distribution in plasma as compared to the healthy calves in two previously published reports. Ultimately, the findings from this study indicate that higher PK/PD indices were predictive of positive treatment outcomes.
机译:本研究的目的是确定(i)当饲养牛被诊断为牛呼吸道疾病(BRD)并用标签剂量和(ii)用gabithromycin(zactran)治疗的饲料牛和(ii)是否血浆中的治疗结果和Gamithromycin浓度之间存在更强的关联或肺上皮衬里液(PELC)效应隔室。该研究设计是一种预期,盲,随机临床试验,可利用三组60(362-592磅)的阉牛/公牛在原始注射或Gamithromycin大规模药物中随机分配。每天对兽医蒙上治疗的兽医的迹象进行评估。达到BRD案例定义的动物被注册并分配给样品收集方案,该样品采集方案组成的细菌分离(支气管肺泡灌洗液和鼻咽拭子)和Gamithromycin浓度测定(PELC和血浆)。使用肉汤微量硅基测定M. Haemolytica(n = 287)和P. MuloCIDA(n = 257)的Gabithromycin易感性。用浓度为0.03至16μg/ ml的浓度的冷冻面板测定多霉菌(n = 257)。使用来自发布和未发表的研究的丰富的数据集,开发了一种双室血浆药代动力学模型,该模板具有额外的POLM中的GAMITHROMYCIN。然后,使用非线性混合效果建模来估计各个参数值​​的非线性混合效果,从我们的研究中的稀疏数据都适合该模型。所得到的参数估计用于模拟本研究中每只动物的全浓度分布。使用非组件方法分析这些型材,从而可以针对每个个人计算PK / PD指数(AUC24 / MIC,AUC&MIC,CMAX / MIC)来计算等离子体和PET(也是T U3患者)。计算出的PK / Pd索引指示M. Hemolytica和P. Multoca在浓度方面的较高药物暴露,并且相对于靶病原体的MIC的暴露持续时间有利于成功的结果。在P. Multocida的治疗成功和Pelf Auc0-24 / MIC之间发现了一个重要的关联。本研究中的小牛在两个先前公布的报告中展示了与健康小牛相比的血浆分布的升高和体积增加。最终,本研究的发现表明,较高的PK / PD指数是预测阳性治疗结果的预测性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号